Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-cash Items (2016 - 2025)

Celldex Therapeutics (CLDX) has 14 years of Non-cash Items data on record, last reported at $42.6 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 44.75% year-over-year to $42.6 million; the TTM value through Dec 2025 reached $42.6 million, down 44.75%, while the annual FY2025 figure was $42.6 million, 44.75% down from the prior year.
  • Non-cash Items reached $42.6 million in Q4 2025 per CLDX's latest filing, down from $72.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $98.6 million in Q4 2023 and bottomed at $1.5 million in Q4 2021.
  • Average Non-cash Items over 5 years is $52.1 million, with a median of $48.9 million recorded in 2022.
  • The widest YoY moves for Non-cash Items: up 4282.03% in 2021, down 93.99% in 2021.
  • A 5-year view of Non-cash Items shows it stood at $1.5 million in 2021, then soared by 2790.84% to $42.9 million in 2022, then surged by 129.84% to $98.6 million in 2023, then decreased by 21.81% to $77.1 million in 2024, then crashed by 44.75% to $42.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $42.6 million in Q4 2025, $72.8 million in Q3 2025, and $81.9 million in Q2 2025.